Voyager's tau-targeted gene therapy VY1706 and anti-tau antibody VY7523 for Alzheimer's Disease to be featured in poster presentations at CTAD 2026. LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) - Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster presentations at the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place in Boston, November 16-19, 2026. The poster presentations will highlight VY1706, Voyager's investigational gene therapy designed to lower tau production in the brain, and VY7523, the Company's clinical stage monoclonal antibody directed against the C-terminal region of tau. CLINICAL TRIALS - PHASE I & IIA First-in-human study design of VY1706, a systemically administered blood-brain barrier (BBB)-penetrant tau lowering gene therapy in early Alzheimer's disease (#P055). Elena Ratti, M.D., MMSc, VP, Clinical Development. Monday, November 16, 2026, 2:00 p.m. - Tuesday, November 17, 2026, 5:30 p.m. ET Baseline characteristics of participants enrolled in a multiple ascending dose study of the C-terminal targeting anti-tau antibody VY7523 in early Alzheimer's disease (#P054). Elena Ratti, M.D., MMSc, VP, Clinical Development. Monday, November 16, 2026, 2:00 p.m. - Tuesday, November 17, 2026, 5:30 p.m. ET The poster presentations will be available on Voyager's website at: https://www.voyagertherapeutics.com/science-publications. About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of - and ultimately cure - neurological diseases. Our pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER(TM) AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com. Voyager Therapeutics(R) is a registered trademark, and TRACER(TM) and Voyager NeuroShuttle(TM) are trademarks, of Voyager Therapeutics, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including, without limitation, implied and express statements about Voyager's belief and expectations regarding the development of its product candidates and advancement of its preclinical and clinical development programs, including Voyager's advancement of the tau silencing gene therapy program in AD, VY1706, including the first-in human study design of VY1706 and timing of achievement of clinical development milestones for VY1706, including initiation of clinical trials and achievement of first-in-human dosing in AD. Voyager's ability to advance its clinical-stage anti-tau antibody program in AD, VY7523; the therapeutic potential, safety, and pharmacological effect of Voyager's current and future product candidates; the mission, goals and value drivers for Voyager's business; and the ability to generate sufficient cash resources to enable Voyager to continue its business and operations through multiple clinical inflection points. The use of words such as "may," "will," "might," "would," "could," "should," "expect," "plan," "anticipate," "believe," "view," "potential," "intend," "seek," "predict," "estimate," "project," "target," or "continue" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All forward-looking statements are based on management's current estimates and assumptions and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from any forward-looking statements in this press release. Factors include, among others, the risks and uncertainties inherent in the development of product candidates, including the initiation, timing, cost, progress, and results of Voyager's planned and future clinical trials including potential delays in timing as a result of slower than expected site initiation, slower than expected enrollment, the need or decision to expand the trials or other changes, which may impact Voyager's ability to meet its expected timelines and may increase its costs; expectations and decisions of regulatory authorities; Voyager's ability to replicate positive results from earlier preclinical studies or clinical trials in current or future clinical trials; potential adverse events Voyager may encounter that could negatively impact development; Voyager's ability to demonstrate that current or future product candidates are safe and effective for their proposed indications; Voyager's scientific approach and continued development of our technology platforms, including the TRACER and non-viral discovery platforms; the development by third parties of capsid identification platforms that may be competitive to our platforms and programs; Voyager's ability to create and protect our intellectual property rights; the progress and success of programs under current or future collaboration and license agreements; the sufficiency of Voyager's cash resources to fund our operations and pursue our corporate objectives; technical and other unexpected hurdles in the development, manufacture and supply of our product candidates, may delay our timing, change our plans, increase our costs, or otherwise negatively impact our business; the ability to attract and retain talented directors, employees, and contractors and the resulting impact to Voyager's business and ability to meet its goals and timelines; any of the foregoing events could impair the drivers and value creation opportunities for Voyager's business. These risks and uncertainties are described in Voyager's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Contacts Company and Investors: Andrea Zuniga, [email protected] Media: Lisa Guiterman, [email protected]

Voyager prepares CEO handoff; Insmed adds Hudson to board. Voyager faces a leadership handoff as Al Sandrock prepares to leave the CEO role but retain his board seat, while Insmed adds Paul Hudson as a director. Key facts. * Voyager CEO transition: Al Sandrock will step down in the first quarter of 2027 and remain on the board. * Insmed board appointment: Insmed is adding Paul Hudson to its board. * VYGR most recent close: 1.74, down 6.45%; October 23, 2026, 20:00 GMT. Currency and listing exchange were not identified in the supplied data. * INSM most recent close: 93.39, down 1.76%; October 23, 2026, 20:00 GMT. Currency and listing exchange were not identified in the supplied data. Al Sandrock will step down as Voyager Therapeutics CEO in the first quarter of 2027 while remaining on its board, and Insmed is adding Paul Hudson as a director. Voyager Therapeutics (VYGR) is preparing for a change in executive leadership without a complete break from its departing chief. Al Sandrock will step down as CEO in the first quarter of 2027 and remain on the board. Separately, Insmed (INSM) is adding Paul Hudson to its board. The distinction between those moves matters. Voyager must manage a transfer of day-to-day authority while retaining its outgoing chief in an oversight role. Insmed is changing its board membership, not announcing a chief executive transition. Neither development, by itself, establishes a change in research priorities, spending or corporate strategy. The leadership developments were reported by Endpoints News. Robin Swartz is Voyager's chief business and operating officer, but the available facts do not establish who will succeed Sandrock. That leaves the identity and mandate of the next CEO as central questions for investors and employees. Voyager must separate executive authority from board continuity. Sandrock's continued board service means he will retain a formal connection to Voyager after leaving its top management position. A director's responsibilities differ from those of a CEO: the board oversees management and major corporate decisions, while the chief executive leads the organization's daily operations and implements strategy. Keeping an outgoing chief on the board can preserve institutional knowledge. It can also make the division of responsibilities especially important. The incoming leader needs room to make operating decisions, while the former chief contributes through the board rather than through an overlapping executive role. Whether that arrangement works well depends on how clearly authority is defined. The announced first-quarter timing gives the transition a broad window, but it does not provide an exact departure date. Nor do the supplied details establish the terms of Sandrock's continuing board service. Those limits matter: remaining a director should not be read as retaining an executive position or receiving a separate advisory assignment. For staff and external counterparties, the practical issue is continuity of decision-making. A leadership handoff can affect whom teams approach for approvals and how priorities are communicated. It need not disrupt operations, but clear reporting lines and a consistent explanation of responsibilities would help distinguish an orderly transition from an unresolved management structure. Swartz's current role is not a confirmed succession announcement. Swartz's position as chief business and operating officer places her in Voyager's senior leadership. The title identifies her current responsibilities; it does not, on its own, establish an appointment as the next chief executive. Treating that distinction carefully avoids turning an incomplete succession picture into a personnel decision that has not been verified. The next meaningful disclosure would identify who will hold executive authority after Sandrock departs and when that authority takes effect. It would also clarify whether other senior responsibilities will change. Those details would allow investors to evaluate the management structure rather than infer it from existing job titles. A successor's mandate would be equally relevant. Maintaining an existing plan and revising it are different assignments, and the available facts do not establish which Voyager intends. Leadership experience can inform that assessment, but a job change alone cannot demonstrate a new strategy. Evidence would need to come from the company's stated priorities and subsequent decisions. Insmed's board addition carries a different test. Maintaining an existing plan and revising it are different assignments, and the available facts do not establish which Voyager intends. At Insmed, the confirmed development is Hudson's addition to the board. That is an oversight change rather than a transfer of operating control. Directors can influence strategy, evaluate management and scrutinize major commitments, but an individual board appointment does not establish that any particular corporate action is planned. The useful questions concern how the appointment fits the board's work. Committee responsibilities, the scope of oversight and the company's explanation of the appointment could help shareholders understand its practical significance. The available facts do not specify those details, so conclusions about Hudson's particular assignment would be premature. Nor should investors treat the appointment as evidence of an impending transaction or management overhaul. Board recruitment can serve several purposes, including adding perspectives and strengthening oversight. Without a stated mandate, the defensible conclusion is narrower: Insmed is adding a director, and the implications will depend on how that director participates in governance. Lower share closes do not establish a leadership verdict. Both companies' shares finished the reported session lower. The supplied market data show Voyager down 6.45% and Insmed down 1.76% at the most recent close, with last trades timestamped October 23, 2026, at 20:00 GMT. These are completed-session figures, not live trading quotations. The wider market also declined: the supplied S&P 500 benchmark was down 0.52%, while the Nasdaq 100 benchmark slipped 0.01%. Those readings provide context for the session, but they do not explain either company's performance or isolate the effect of the leadership news. A closing move records the outcome of trading, not investors' reasons for buying or selling. The supplied information does not establish how much, if any, of either decline was attributable to these personnel changes. Calling the losses a rejection of the appointments would go beyond the evidence. The next disclosures should clarify responsibility and mandate. For Voyager, the priority is a clear succession framework: who becomes CEO, when the handoff occurs and how Sandrock's board role will coexist with the new leader's authority. Investors should distinguish those governance details from any later announcement about business priorities. One does not automatically establish the other. For Insmed, the focus is how Hudson's appointment translates into board responsibilities. Across both companies, the immediate story is about accountability and continuity rather than a demonstrated change in scientific or commercial prospects. The most useful follow-up will connect named leaders to defined duties - and show whether operating plans remain intact. Frequently asked questions. When will Al Sandrock leave Voyager's CEO role? Al Sandrock will step down as Voyager Therapeutics CEO in the first quarter of 2027. The available facts do not provide an exact departure date. He will remain on Voyager's board, preserving a formal governance role after he leaves responsibility for day-to-day executive leadership. Has Robin Swartz been confirmed as Voyager's next CEO? The supplied facts identify Robin Swartz as Voyager Therapeutics' chief business and operating officer but do not confirm her as the next CEO. Her current title should not be treated as a succession announcement. A confirmed appointment and effective date would be needed to establish who will replace Al Sandrock. What does Sandrock's continued board service mean? Remaining on Voyager's board gives Al Sandrock an ongoing oversight role after his departure as CEO. It does not, by itself, mean he will retain executive authority or receive an advisory assignment. The practical implications depend on how the board and incoming management define their respective responsibilities. What leadership change is Insmed making? Insmed is adding Paul Hudson to its board. The confirmed development concerns board membership, not a CEO replacement or transfer of daily operating authority. The supplied facts do not specify Hudson's committee assignments or establish that his appointment signals a transaction, strategic overhaul or other corporate action. How did Voyager and Insmed shares finish the session? Voyager shares closed down 6.45%, and Insmed shares closed down 1.76%, according to supplied market data timestamped October 23, 2026, at 20:00 GMT. Those figures describe the completed trading session. They do not establish that the leadership developments caused either decline or reveal investors' individual reasons for trading. What should investors watch for next? At Voyager, investors should look for a confirmed successor, an effective handoff date and a clear division between the new CEO's authority and Sandrock's board responsibilities. At Insmed, further detail about Hudson's board duties would help explain the appointment. Neither personnel change alone proves that business priorities will change.